Allogene Therapeutics, Inc. — Director's Dealing 2021

May 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-05-24

Reporting Person: SCHMIDT ERIC THOMAS (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-24	Common Stock	M	14897	$18.22	Acquired	110994	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-24	Stock Option (Right to Buy)	$18.22	M	14897	Disposed	2030-03-18	Common Stock (14897)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1152595	Indirect

Footnotes

F1: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust.

F2: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.